Scarica l'app Stockscreener
2.00
0.50%
0.01
Dopo l'orario di chiusura:
1.92
-0.08
-4.00%
Precedente Chiudi:
$1.99
Aprire:
$1.93
Volume 24 ore:
1.15M
Relative Volume:
0.77
Capitalizzazione di mercato:
$242.53M
Reddito:
$79,600
Utile/perdita netta:
$-47.66M
Rapporto P/E:
-3.5063
EPS:
-0.5704
Flusso di cassa netto:
$-26.07M
1 W Prestazione:
+6.38%
1M Prestazione:
+19.76%
6M Prestazione:
+28.21%
1 anno Prestazione:
-9.09%
Intervallo 1D:
$1.86
$2.02
Intervallo di 1 settimana:
$1.80
$2.03
Portata 52W:
$1.33
$2.58
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Nome
Inhibikase Therapeutics Inc
Settore
Industria
Telefono
(302) 295-3800
Indirizzo
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
2.00 | 242.53M | 79,600 | -47.66M | -26.07M | -0.5704 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-04 | Iniziato | Ladenburg Thalmann | Buy |
| 2026-01-21 | Iniziato | BofA Securities | Buy |
| 2025-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2025-12-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Borsa (IKT) Ultime notizie
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Up 52.2% in February - MarketBeat
Aug Ideas: Does Inhibikase Therapeutics Inc stock benefit from AI growth2026 Retail & Low Drawdown Trading Techniques - baoquankhu1.vn
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Analysts - MarketBeat
Reviewing Athira Pharma (NASDAQ:LONA) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
Inhibikase Therapeutics (NASDAQ:IKT) Stock Rating Upgraded by LADENBURG THALM/SH SH - Defense World
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to "Strong-Buy" at LADENBURG THALM/SH SH - MarketBeat
Inhibikase Therapeutics (IKT) Gains New Coverage with 'Buy' Rati - GuruFocus
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Update - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Coverage Initiated at LADENBURG THALM/SH SH - MarketBeat
Ladenburg Thalmann Initiates Inhibikase Therapeutics at Buy - marketscreener.com
Athira Pharma (NASDAQ:LONA) versus Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Analysis - Defense World
FY2025 Earnings Forecast for IKT Issued By Lifesci Capital - Defense World
A Look At Inhibikase Therapeutics (IKT) Valuation After New FDA Designations And Phase 2a Trial Progress - simplywall.st
Inhibikase Therapeutics (NYSE:IKT) Trading Up 4.4%Still a Buy? - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Trading Up 4.4% – Still a Buy? - Defense World
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded by Lifesci Capital to "Strong-Buy" Rating - MarketBeat
Analyzing Athira Pharma (NASDAQ:LONA) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
IKT Stock Surge: What’s Driving the 13% Jump Today? - Creative Learning Guild
Inhibikase (IKT) R&D president forfeits 338,282 milestone-based shares - Stock Titan
Inhibikase (IKT) director Amit Munshi forfeits 19,089 milestone-based shares - Stock Titan
IKT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IKT Stock Bounces Amid Steady Growth Potential - StocksToTrade
Inhibikase Therapeutics: A Surge in Market Interest on Recent Developments - timothysykes.com
IKT Surges Amid Strategic Developments and Market Shifts - StocksToTrade
Inhibikase Therapeutics Stock Faces Challenges Amid Financial Uncertainty - timothysykes.com
Certain Warrants of Inhibikase Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-FEB-2026. - marketscreener.com
ADAR1 group discloses 9.9% Inhibikase (IKT) ownership via shares and warrants - Stock Titan
Fairmount discloses 9.9% Inhibikase (IKT) stake via shares and warrants - Stock Titan
Will Inhibikase Therapeutics Inc. stock deliver consistent dividendsMarket Sentiment Review & Technical Buy Zone Confirmations - mfd.ru
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
[SCHEDULE 13G/A] Inhibikase Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Does Inhibikase Therapeutics Inc. stock benefit from AI growthChart Signals & Free Expert Approved Momentum Trade Ideas - mfd.ru
Inhibikase Therapeutics (NASDAQ:IKT) Trading Up 6.9%Time to Buy? - MarketBeat
Aug Big Picture: Can Inhibikase Therapeutics Inc sustain its profitability2025 Valuation Update & Entry Point Confirmation Signals - baoquankhu1.vn
What’s next for Inhibikase Therapeutics Inc. stockWeekly Profit Recap & High Conviction Investment Ideas - mfd.ru
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Pfizer (PFE) and Inhibikase Therapeutics (IKT) - The Globe and Mail
Aug Chart Watch: Is Inhibikase Therapeutics Inc a potential multi baggerJuly 2025 WrapUp & Target Return Focused Stock Picks - baoquankhu1.vn
Guidance Update: Is Precision Drilling Corporation affected by consumer sentimentEarnings Overview Summary & Weekly High Potential Alerts - baoquankhu1.vn
Risk Report: Does Inhibikase Therapeutics Inc stock benefit from AI growth2025 Market Outlook & Smart Investment Allocation Insights - baoquankhu1.vn
Market Outlook: Is HCA Healthcare Inc stock a smart retirement pickJuly 2025 Movers & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
What drives Inhibikase Therapeutics Inc.’s stock priceQuarterly Trade Report & Short-Term High Return Ideas - mfd.ru
B of A Securities Initiates Coverage of Inhibikase Therapeutics (IKT) with Buy Recommendation - Nasdaq
BofA Securities initiates coverage on Inhibikase stock with Buy rating By Investing.com - Investing.com South Africa
Inhibikase Therapeutics (NYSE:IKT) Earns Buy Rating from Analysts at Bank of America - MarketBeat
B of A Securities Initiates Coverage on IKT with 'Buy' Rating | - GuruFocus
BofA Securities initiates coverage on Inhibikase stock with Buy rating - Investing.com
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
What analyst consensus says on Inhibikase Therapeutics Inc. stockQuarterly Profit Report & Expert Curated Trade Ideas - Bollywood Helpline
Can Inhibikase Therapeutics Inc. stock sustain free cash flow growthMarket Growth Report & Daily Stock Momentum Reports - bollywoodhelpline.com
RSI Check: Does Inhibikase Therapeutics Inc outperform in volatile marketsMarket Growth Report & High Accuracy Investment Signals - baoquankhu1.vn
Inhibikase Therapeutics Inc Azioni (IKT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):